Natural Remedies for Hot Flushes

Hot Flash Remedy report

Heres what youll discover in The Hot Flash Remedy report: The herb from central Asia that can stop hot flashes in one week! (page 17) How your brain gets tricked into firing up the furnace and how to recalibrate it. (page 6) 7 lifestyle factors that increase your odds of suffering from hot flashes. (page 19) 9 food items that bring hot flashes on fast and furious! (page 10) The bean that actually makes hot flashes non-existent for women in other countries. (page 12) The secret ingredient in your fruit bowl that extinguishes the flame. (page 17) Why 6 meals a day are better than 3 and eating more often wont make you gain weight! (page 10) How common wildflowers hold the key to shutting down hot flashes. (page 16)

Hot Flash Remedy report Summary


4.6 stars out of 11 votes

Format: Ebook
Price: $27.77

My Hot Flash Remedy report Review

Highly Recommended

I've really worked on the chapters in this ebook and can only say that if you put in the time you will never revert back to your old methods.

Overall my first impression of this ebook is good. I think it was sincerely written and looks to be very helpful.

Download Now

Experimental Disease Models

The interaction of the estrogen receptor with its natural ligand, 17 -estradiol (E2), mediates a number of fundamental physiological processes, including regulation of the female reproductive system and the maintenance of skeletal and cardiovascular health. Pharmacological modulation of the estrogen receptor with the estrogens found in hormone replacement therapy (HRT) provides important clinical benefits in women for the treatment of hot flashes and osteoporosis. However, the increased risk of breast, uterine, and cardiovascular side effects that is associated with estrogen therapies has led to the development of ligands with improved risk-to-benefit ratios. These SERMs, such as tamoxifen and raloxifene, have demonstrated the ability to mimic estrogen in some tissues (bone, liver, and the cardiovascular system) while suppressing the effects of estrogen in other tissues (breast, uterus Figure 1). This unique tissue-selective profile has proven beneficial for the prevention and...

Development of Gabapentin for Epilepsy

After the gabapentin product launch, gabapentin was used extensively by physicians for treating epilepsy. Because of a relatively benign adverse event profile and few drug-drug interactions, it was also prescribed for off-label indications, including neuropathic pain, anxiety, and other psychiatric indications, essential tremor, spasticity, postsurgical pain, and prevention of postmenopausal hot flashes. None of these additional indications were supported in the gabapentin product labeling or approved by regulatory agencies until the FDA approved a supplemental NDA for gabapentin to treat postherpetic neuralgia in July 2001 (see Section, below).

Tamoxifen and Breast Cancer Prevention

An assessment of quality of life showed no difference in depression scores between groups. Hot flushes were noted in 81 of the women on tamoxifen compared to 69 of the placebo group and the tamoxifen-associated hot flushes appeared to be of greater severity than those in the placebo group. Moderately bothersome or severe vaginal discharge was reported by 29 of the women in tamoxifen group and 13 in the placebo group. No differences in occurrence of irregular menses, nausea, fluid retention, skin changes, or weight gain or loss were

Sleep Disturbance In

Diarrhea is a common complaint of patients living with opportunistic infections and can lead to fragmented and non-restful sleep, as can urinary frequency, hot flashes, muscle cramping, pruritus, dyspnea, and other physical complaints. Obstructive sleep ap-nea due to adenotonsillar hypertrophy has been estimated to have a prevalence of 7 among individuals living with HIV, even in the absence of obesity (Epstein et al., 1995). It has also been associated with increased neck fat hypertrophy, which is due to the deposit of adipose tissue around the neck as part of HIV-associated lipodystrophy (Schulz et al., 2003). Decreased levels of testosterone can also lead to insomnia.

Physiological Effects

The plateau stage of drug effects lasts 3-4 hours. The principal desired effect, according to most users, is a profound feeling of relatedness to the rest of the world. Most users experience this feeling as a powerful connection to those around them, as well as to the universe (Leister, Grob, Bravo, & Walsh, 1992). Although the desire for sex can increase, the ability to achieve arousal and orgasm is greatly diminished in both men and women (Buffum & Moser, 1986). MDMA has thus been termed a sensual, not a sexual, drug. The prescription drug sildenafil (Viagra) may be taken in order to counteract this effect, and may be sold along with MDMA (Weir, 2000) the successor medications involving sexual enhancement can be expected to be used in this manner. The array of physical effects and behaviors produced by MDMA is remarkably similar across mammalian species (Green et al., 1995) and includes mild psychomotor restlessness, bruxism, trismus, anorexia, diaphoresis, hot flashes,...

Endocrine Disorders Associated with Myofascial Pain

Menopause, secondary to estrogenic insufficiency may be difficult for the patient and associated with myofascial pain and TrPs, sweats, and hot flashes. On occasion, muscle pain, and or joint pain may be the primary complaints. Associated symptoms may include anxiety, weakness, depression, emotional difficulties, and loss of libido. These symptoms typically all improve with exogenous estrogen replacement.

Background and Introduction

The female sex hormone estrogen plays an essential role in reproduction and is important for the overall maintenance of physiologic homeostasis in a woman's body.1'2 During menopause, which occurs in women at an average age of 51, the amount of estrogen produced by the ovaries decreases and this estrogen deficiency causes menstrual periods to become less frequent and then stop.3-5 The loss of estrogen is responsible for many of the uncomfortable symptoms associated with menopause, including hot flashes, mood swings or depression, sleep disorders, vaginal dryness, and urinary dysfunction.6 Osteoporosis or bone loss is another consequence of reduced estrogen levels after menopause.7-11 In women, bone density increases until ages 30-35,12 but slowly declines after menopause.13 Postmenopausal women are also at increased risk for coronary heart disease (CHD)14,15 and Alzheimer's disease,16-18 as a result of estrogen deficiency. The realization that the symptoms reported by postmenopausal...

Hormonal Therapy

Reduced risk of deep-vein and arterial thrombosis, hot flashes, and vaginal secretion. Of concern is the observation that the nonsteroidal aromatase inhibitors letrozole and anastrazol seem to enhance the risk of osteoporosis and bone fractures. The long-term effects of these compounds on cognition and serum lipids are unknown and cause some concerns, especially for women with long life-expectancy. Also, in the case of faslodex, the risk of endometrial cancer and thrombosis is significantly reduced compared to tamoxifen while its effects on bones,lipids, and cognition are unknown. Faslodex is active in approximately 20 of patients whose cancer progressed whilst receiving tamoxifen. The role of this agent in the adjuvant setting has not been clarified.


Menopause is the permanent cessation of the menstrual periods that occurs around age 50 in most women. As a woman moves into her late 40s, her body's estrogen production slows down, and she gradually stops ovulating. Symptoms of the menopause include hot flashes, headaches, fatigue, vaginal irritation, mood swings, and depression. These symptoms can range from mild to severe about one in five women seek medical attention for symptoms of the menopause. A major concern at the menopause is the loss of bone mineral (mainly calcium) from the skeleton due to the loss of estrogens.21 Up to 20 of the bone mineral density can be lost at menopause, which can sharply increase risk of osteoporosis and bone fractures. The loss of estrogen at menopause also causes LDL cholesterol levels in the blood to rise and levels of HDLcho-

Gemtuzumab zoqamicin

Goserelin -LHRH agonist -endocrine effects -hot flashes -decreased libido -gynecomastia -impotence -nausea and vomiting (uncommon) -transient increase in bone pain -hot flashes -decreased libido -gynecomastia (3 ) -breast tenderness -impotence (2 ) -nausea and vomiting (uncommon) -transient increase in bone pain -peripheral edema -dizziness, headache -hot flashes


Bazedoxifene (TSE-424 Figure 10) is a novel SERM developed by Wyeth Pharmaceuticals that is currently in phase III clinical trials for the prevention and treatment of postmenopausal osteoporosis. It is an indole-based estrogen receptor ligand that has been stringently selected to ensure an improved profile over its predecessor raloxifene. It was developed using preclinical selection parameters, which included favorable effects on the skeleton and lipid metabolism, demonstrable mammary and uterine safety, and neutral effects on hot flashes.192 Bazedoxifene treatment maintains bone mineral density, preserves normal bone histology, increases bone compressive strength, and reduces total cholesterol levels in animal models.192-194 It lacks uterotropic activity194 and it blocks raloxifene-induced increases in uterine weight192 and inhibits E2-induced proliferation in MCF-7 breast cancer cells.192 Based on the favorable preclinical evaluation, it is suggested that bazedoxifene has the...